Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.41 |
| ▸ | WNT1 | P04628 | 3/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6277247 | 0.91 | MMP9 (0.43) | ABL1CSF1RIGF1RPDGFRBKIT | |
| SCHEMBL4532307 | 0.89 | TP53 (0.45) | KDRMMP9MMP1MAPTSMN1; SMN2 | |
| SCHEMBL951815 | 0.88 | GRM5 (0.39) | ROCK2NAMPTMAPTGRM5ROCK1 | |
| SCHEMBL953339 | 0.86 | CYP11B1 (0.46) | CYP11B1CYP11B2WNT1DYRK1ANTSR1 | |
| SCHEMBL4521537 | 0.86 | FLT1 (0.44) | ABL1CSF1RIGF1RPDGFRBKIT | |
| SCHEMBL953701 | 0.86 | PIK3C3 (0.41) | DYRK1ANAMPTMAPTGRM5 | |
| SCHEMBL954050 | 0.85 | GRM5 (0.37) | ABL1CSF1RKITFGFR1FLT1 | |
| SCHEMBL4518203 | 0.84 | LMNA (0.39) | ABL1CSF1RIGF1RPDGFRBKIT | |
| SCHEMBL4531463 | 0.84 | GRM5 (0.36) | ROCK2NAMPTMAPTGRM5 | |
| SCHEMBL27655692 | 0.84 | DYRK1A (0.43) | FGFR1KDRWNT1DYRK1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021467-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| US-7842711-B2 | Indazolecarboxamide derivatives for the treatment and prevention of malaria | SANOFI-AVENTIS (FR) | 2010-11-30 | — | — | US | disclosed |
| US-7482342-B2 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2009-01-27 | — | — | US | disclosed |
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| EP-1727544-A1 | USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT THAT IS INTENDED FOR THE TREATMENT AND PREVENTION OF PALUDISM | Sanofi-Aventis (FR) | 2006-12-06 | — | — | EP | disclosed |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2006-01-05 | — | — | US | disclosed |
| WO-2005099703-A1 | USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT THAT IS INTENDED FOR THE TREATMENT AND PREVENTION OF PALUDISM | SANOFI-AVENTIS (FR) | 2005-10-27 | — | — | WO | disclosed |
| EP-1549620-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | Sanofi-Aventis (FR) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031158-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | SANOFI-AVENTIS (FR) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | CYP3A43, CYP3A5, SIRT5 | ABL1 647/4885CSF1R 2062/4885IGF1R 3523/4885 |
| US-20110021467-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | CYP3A43, CYP3A5, SIRT5 | ABL1 647/4885CSF1R 2062/4885IGF1R 3523/4885 |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | CDK2, CDK1, CDK4 | ABL1 242/4885CSF1R 2475/4885IGF1R 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.